{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:13:52Z","timestamp":1771460032810,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41409-020-01181-x","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T05:02:38Z","timestamp":1608267758000},"page":"1297-1304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-4401","authenticated-orcid":false,"given":"Sebastian","family":"Giebel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2007-7609","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Sobczyk-Kruszelnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u0142awomir","family":"Blamek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sadu\u015b-Wojciechowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Najda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Czerw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u0142odzimierz","family":"Mendrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017cena","family":"Jochymek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Leszczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Dolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"\u015alosarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Ho\u0142owiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leszek","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"1181_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91\u201397.","journal-title":"N Engl J Med"},{"key":"1181_CR2","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1617\u201329.","journal-title":"Lancet Oncol"},{"key":"1181_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben, Yehuda D, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895\u2013905.","journal-title":"N Engl J Med"},{"key":"1181_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-01-763219","volume":"130","author":"M Cavo","year":"2017","unstructured":"Cavo M, H\u00e1jek R, Pantani L, Beksac M, Oliva S, Dozza L, et al. Autologous stem-cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02\/HO95 study. Blood. 2017;130:397.","journal-title":"Blood"},{"key":"1181_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"1181_CR6","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/S2352-3026(17)30080-7","volume":"4","author":"Y Nieto","year":"2017","unstructured":"Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, et al. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017;4:e283\u201392.","journal-title":"Lancet Haematol"},{"key":"1181_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731\u20135.","journal-title":"Blood"},{"key":"1181_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbmt.2005.10.026","volume":"12","author":"JY Wong","year":"2006","unstructured":"Wong JY, Liu A, Schultheiss T, Popplewell L, Stein A, Rosenthal J, et al. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transpl. 2006;12:306\u201315.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1181_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijrobp.2008.04.071","volume":"73","author":"JY Wong","year":"2009","unstructured":"Wong JY, Rosenthal J, Liu A, Schultheiss T, Forman S, Somlo G. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2009;73:273\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1181_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1078-0432.CCR-10-1912","volume":"17","author":"G Somlo","year":"2011","unstructured":"Somlo G, Spielberger R, Frankel P, Karanes C, Krishnan C, Parker P, et al. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res. 2011;17:174\u201382.","journal-title":"Clin Cancer Res"},{"key":"1181_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/bmt.2012.269","volume":"48","author":"S Giebel","year":"2013","unstructured":"Giebel S, Kruzel T, Czerw T, Sadus-Wojciechowska M, Najda J, Chmielowska E, et al. Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Bone Marrow Transpl. 2013;48:915\u201321.","journal-title":"Bone Marrow Transpl"},{"key":"1181_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.bbmt.2018.09.023","volume":"25","author":"T Czerw","year":"2019","unstructured":"Czerw T, Sadus-Wojciechowska M, Michalak K, Najda J, Mendrek W, Sobczyk-Kruszelnicka M, et al. Increased efficacy of stem-cell chemomobilization with intermediate-dose cytarabine plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone in patients with multiple myeloma: results of a randomized trial. Biol Blood Marrow Transpl. 2019;25:248\u201355.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1181_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41409-017-0056-6","volume":"53","author":"I Mitrus","year":"2018","unstructured":"Mitrus I, Smagur A, Fidyk W, Czech M, Prokop M, Chwieduk A, et al. Reduction of DMSO concentration in cryopreservation mixture from 10% to 7.5 and 5% has no impact on engraftment after autologous peripheral blood stem cell transplantation: results of a prospective, randomized study. Bone Marrow Transpl. 2018;53:274\u201380.","journal-title":"Bone Marrow Transpl"},{"key":"1181_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cryobiol.2013.09.167","volume":"63","author":"I Mitrus","year":"2013","unstructured":"Mitrus I, Smagur A, Giebel S, Gliwinska J, Prokop M, Glowala-Kosinska M, et al. A faster reconstitution of hematopoiesis after autologous transplantation of hematopoietic cells cryopreserved in 7.5% dimethyl sulfoxide if compared to 10% dimethyl sulfoxide containing medium. Cryobiology. 2013;63:327\u201331.","journal-title":"Cryobiology"},{"key":"1181_CR15","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1118\/1.2044428","volume":"32","author":"SK Hui","year":"2005","unstructured":"Hui SK, Kapatoes J, Fowler J, Henderson D, Olivera G, Manon RR, et al. Feasibility study of helical tomotherapy for total body or total marrow irradiation. Med Phys. 2005;32:3214\u201324.","journal-title":"Med Phys"},{"key":"1181_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5603\/NJO.2014.0052","volume":"64","author":"G G\u0142owacki","year":"2014","unstructured":"G\u0142owacki G, Miszczyk L, \u015alosarek K, Jochymek B, Wo\u017aniak G, Matulewicz \u0141, et al. Method of total marrow irradiation (TMI). Nowotw J Oncol. 2014;64:314\u201320.","journal-title":"Nowotw J Oncol"},{"key":"1181_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"1181_CR18","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","volume":"115","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, et al. Melphalan 200 mg\/m2 versus melphalan 100 mg\/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood. 2010;115:1873\u20139.","journal-title":"Blood"},{"key":"1181_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3324\/haematol.2017.181339","volume":"103","author":"HW Auner","year":"2018","unstructured":"Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, et al. Melphalan 140 mg\/m(2) or 200 mg\/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018;103:514\u201321.","journal-title":"Haematologica"},{"key":"1181_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41409-018-0261-y","volume":"54","author":"P Hari","year":"2019","unstructured":"Hari P, Reece DE, Randhawa J, Knol-Bout C, Blaise D, Russell NH, et al. Final outcomes of escalated melphalan 280 mg\/m2 with amifostine cytoprotection followed autologous hematopoietic stem-cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. Bone Marrow Transplant. 2019;54:293\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1181_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ijrobp.2018.06.015","volume":"102","author":"Y Belkacemi","year":"2018","unstructured":"Belkacemi Y, Labopin M, Giebel S, Loganadane G, Miszczyk L, Michallet M, et al. Single-dose daily fractionation is not inferior to twice-a-day fractionated total-body irradiation before allogeneic stem cell transplantation for acute leukemia: a useful practice simplification resulting from the SARASIN study. Int J Radiat Oncol Biol Phys. 2018;102:515\u201326.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1181_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbmt.2015.09.014","volume":"22","author":"HM Chaudhry","year":"2016","unstructured":"Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review. Biol Blood Marrow Transpl. 2016;22:605\u201316.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1181_CR23","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","volume":"95","author":"JJ Lahuerta","year":"2010","unstructured":"Lahuerta JJ, Mateos MV, Mart\u00ednez-L\u00f3pez J, Grande C, de la Rubia J, Rosi\u00f1ol L, et al. Busulfan 12 mg\/kg plus melphalan 140 mg\/m2 versus melphalan 200 mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study. Haematologica. 2010;95:1913\u201320.","journal-title":"Haematologica"},{"key":"1181_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbmt.2012.08.009","volume":"19","author":"M Blanes","year":"2013","unstructured":"Blanes M, Lahuerta JJ, Gonz\u00e1lez JD, Ribas P, Solano C, Alegre A, et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transpl. 2013;19:69\u201374.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1181_CR25","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","volume":"115","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, et al. Melphalan 200 mg\/m(2) versus melphalan 100 mg\/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood. 2010;115:1873\u20139.","journal-title":"Blood"},{"key":"1181_CR26","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434\u201341.","journal-title":"J Clin Oncol"},{"key":"1181_CR27","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495\u2013502.","journal-title":"N Engl J Med"},{"key":"1181_CR28","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/bmt.2016.94","volume":"51","author":"M Martino","year":"2016","unstructured":"Martino M, Tripepi G, Messina G, Vincelli ID, Console G, Recchia AG, et al. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Bone Marrow Transpl. 2016;51:1197\u2013203.","journal-title":"Bone Marrow Transpl"},{"key":"1181_CR29","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.bbmt.2016.03.021","volume":"22","author":"TE Rodriguez","year":"2016","unstructured":"Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH. Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transpl. 2016;22:1391\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1181_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37:589\u201397.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01181-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:22Z","timestamp":1684617442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01181-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01181-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"assertion":[{"value":"2 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}